Q702 for the Treatment of Patients With Hematologic Malignancies
Public ClinicalTrials.gov record NCT06712810. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies With Q702, a Small Molecular Inhibitor
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.
Study identification
- NCT ID
- NCT06712810
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 46 participants
Conditions and interventions
Conditions
- Hematopoietic and Lymphatic System Neoplasm
- Histiocytic Sarcoma
- Malignant Histiocytosis
- Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Chronic Myelomonocytic Leukemia
- Recurrent Follicular Lymphoma
- Recurrent Langerhans Cell Histiocytosis
- Recurrent Lymphoplasmacytic Lymphoma
- Recurrent Myelodysplastic Syndrome
- Recurrent Myelofibrosis
- Recurrent Small Lymphocytic Lymphoma
- Recurrent Waldenstrom Macroglobulinemia
- Refractory Chronic Lymphocytic Leukemia
- Refractory Chronic Myelomonocytic Leukemia
- Refractory Erdheim-Chester Disease
- Refractory Follicular Lymphoma
- Refractory Langerhans Cell Histiocytosis
- Refractory Lymphoplasmacytic Lymphoma
- Refractory Myelodysplastic Syndrome
- Refractory Myelofibrosis
- Refractory Small Lymphocytic Lymphoma
- Refractory Waldenstrom Macroglobulinemia
- Rosai-Dorfman-Destombes Disease
- Primary Central Nervous System Lymphoma
- Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
- Recurrent Erdheim-Chester Disease
- Recurrent Fibroblastic Reticular Cell Sarcoma
- Recurrent Histiocytic Sarcoma
- Recurrent Interdigitating Dendritic Cell Sarcoma
- Recurrent Rosai-Dorfman-Destombes Disease
- Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
- Refractory Fibroblastic Reticular Cell Sarcoma
- Refractory Histiocytic Sarcoma
- Refractory Interdigitating Dendritic Cell Sarcoma
- Refractory Rosai-Dorfman-Destombes Disease
Interventions
- Axl/Mer/CSF1R Inhibitor Q702 Drug
- Biospecimen Collection Procedure
- Bone Marrow Aspiration Procedure
- Bone Marrow Biopsy Procedure
- Computed Tomography Procedure
- Magnetic Resonance Imaging Procedure
- Positron Emission Tomography Procedure
- Survey Administration Other
Drug · Procedure · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 26, 2025
- Primary completion
- Sep 14, 2030
- Completion
- Sep 14, 2030
- Last update posted
- Oct 9, 2025
2025 – 2030
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Arizona | Scottsdale | Arizona | 85259 | Recruiting |
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06712810, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 9, 2025 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06712810 live on ClinicalTrials.gov.